1. Home
  2. IMMP vs CLW Comparison

IMMP vs CLW Comparison

Compare IMMP & CLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • CLW
  • Stock Information
  • Founded
  • IMMP 1987
  • CLW 2005
  • Country
  • IMMP Australia
  • CLW United States
  • Employees
  • IMMP N/A
  • CLW N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • CLW Paper
  • Sector
  • IMMP Health Care
  • CLW Basic Materials
  • Exchange
  • IMMP Nasdaq
  • CLW Nasdaq
  • Market Cap
  • IMMP 256.1M
  • CLW 293.0M
  • IPO Year
  • IMMP N/A
  • CLW N/A
  • Fundamental
  • Price
  • IMMP $1.90
  • CLW $18.23
  • Analyst Decision
  • IMMP Buy
  • CLW Strong Buy
  • Analyst Count
  • IMMP 1
  • CLW 2
  • Target Price
  • IMMP $7.00
  • CLW $30.00
  • AVG Volume (30 Days)
  • IMMP 128.2K
  • CLW 204.0K
  • Earning Date
  • IMMP 02-22-2026
  • CLW 10-28-2025
  • Dividend Yield
  • IMMP N/A
  • CLW N/A
  • EPS Growth
  • IMMP N/A
  • CLW 875.72
  • EPS
  • IMMP N/A
  • CLW 8.63
  • Revenue
  • IMMP $3,306,742.00
  • CLW $1,556,100,000.00
  • Revenue This Year
  • IMMP N/A
  • CLW $13.91
  • Revenue Next Year
  • IMMP N/A
  • CLW N/A
  • P/E Ratio
  • IMMP N/A
  • CLW $2.13
  • Revenue Growth
  • IMMP 31.28
  • CLW 23.00
  • 52 Week Low
  • IMMP $1.32
  • CLW $16.44
  • 52 Week High
  • IMMP $2.71
  • CLW $33.57
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 56.87
  • CLW 48.96
  • Support Level
  • IMMP $1.68
  • CLW $16.44
  • Resistance Level
  • IMMP $1.95
  • CLW $17.61
  • Average True Range (ATR)
  • IMMP 0.09
  • CLW 0.75
  • MACD
  • IMMP 0.01
  • CLW 0.06
  • Stochastic Oscillator
  • IMMP 82.14
  • CLW 71.16

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About CLW Clearwater Paper Corporation

Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.

Share on Social Networks: